Search - tctmd.com

Displaying 101 - 120 of 465

Sort: Relevancy | Date

Presentation TCT 2023

Trialist Perspectives

Presenter: Felix Mahfoud

October 24, 2023

Presentation TCT 2023

From First Gen to Next Gen: New Devices on the Horizon

Presenter: Felix Mahfoud

October 24, 2023

Presentation TCT 2023

Securing Reimbursement: The Pathway to Financial Stability

Presenter: David Kandzari

October 24, 2023

Presentation TCT 2023

Creating Training Pathways for the Proceduralist

Presenter: Herbert Aronow

October 24, 2023

Presentation TCT 2023

Where Do We Go From Here? Evolving the Hypertension Program

Presenter: Michael Bloch

October 24, 2023

Presentation TCT 2023

Who Is the Perfect Candidate for RDN? A Case-Based Discussion

Presenter: Michel Azizi

October 24, 2023

Presentation TCT 2023

Controlling the Uncontrolled: How Big Is the RDN Population?

Presenter: Naomi Fisher

October 24, 2023

Presentation EuroPCR 2023

Effectiveness and Safety of the NetrodTM Six-Electrode Radiofrequency Renal Denervation System for the Treatment of Uncontrolled Essential Hypertension

Presenter: Yu-Jie Zhou

May 17, 2023

Presentation Miami Valves 2023

What’s New In Renal Denervation?

Presenter: Sergio Perez

February 04, 2023

Presentation AHA 2022

Renal Denervation in the Presence of Anti-Hypertensive Medications: Six-Month Results from the Randomized, Blinded, Sham-Controlled SPYRAL HTN – ON MED Trial

Presenter: David E. Kandzari

November 07, 2022

Presentation TCT 2022

Discussion - What does this Field Need Next?

Presenter: Felix Mahfoud

September 19, 2022

Presentation TCT 2022

Who Should be Treated with uRDN?

Presenter: Naomi Fisher

September 19, 2022

Presentation TCT 2022

Discussion - Key Takeaways from the RADIANCE Clinical Program

Presenter: Felix Mahfoud

September 19, 2022

Presentation TCT 2022

Late-Breaking Evidence from RADIANCE II

Presenter: Michel Azizi

September 19, 2022

Presentation TCT 2022

Introduction and Objectives

Presenter: Felix Mahfoud

September 19, 2022

Presentation TCT 2022

NEXT STEPS: How Will Renal Denervation be Implemented in Practice?

Presenter: Naomi Fisher

September 18, 2022

Presentation TCT 2022

Clinical Implications of RADIANCE II and Recent Renal Denervation Trials: A Clinician’s Perspective

Presenter: Patrick O'Gara

September 18, 2022

Presentation TCT 2022

Long-Term Outcomes Following Catheter-Based Renal Denervation in Patients With Uncontrolled Hypertension: 3-Year Follow-up of the SYMPLICITY HTN-3 Trial

Presenter: Deepak Bhatt

September 18, 2022

Presentation TCT 2022

Endovascular Ultrasound Renal Denervation to Treat Uncontrolled Hypertension: Primary Results of the Randomized, Sham-Controlled RADIANCE II Pivotal Trial

Presenter: Ajay Kirtane

September 18, 2022

Presentation TCT 2022

Update on the RADIANCE Clinical Trials Program (Ultra-Sound Renal Denervation)

Presenter: Naomi Fisher

September 17, 2022

Advertisement

Trialist Perspectives

From First Gen to Next Gen: New Devices on the Horizon

Securing Reimbursement: The Pathway to Financial Stability

Creating Training Pathways for the Proceduralist

Where Do We Go From Here? Evolving the Hypertension Program

Who Is the Perfect Candidate for RDN? A Case-Based Discussion

Controlling the Uncontrolled: How Big Is the RDN Population?

Effectiveness and Safety of the NetrodTM Six-Electrode Radiofrequency Renal Denervation System for the Treatment of Uncontrolled Essential Hypertension

What’s New In Renal Denervation?

Renal Denervation in the Presence of Anti-Hypertensive Medications: Six-Month Results from the Randomized, Blinded, Sham-Controlled SPYRAL HTN – ON MED Trial

Discussion - What does this Field Need Next?

Who Should be Treated with uRDN?

Discussion - Key Takeaways from the RADIANCE Clinical Program

Late-Breaking Evidence from RADIANCE II

Introduction and Objectives

NEXT STEPS: How Will Renal Denervation be Implemented in Practice?

Clinical Implications of RADIANCE II and Recent Renal Denervation Trials: A Clinician’s Perspective

Long-Term Outcomes Following Catheter-Based Renal Denervation in Patients With Uncontrolled Hypertension: 3-Year Follow-up of the SYMPLICITY HTN-3 Trial

Endovascular Ultrasound Renal Denervation to Treat Uncontrolled Hypertension: Primary Results of the Randomized, Sham-Controlled RADIANCE II Pivotal Trial

Update on the RADIANCE Clinical Trials Program (Ultra-Sound Renal Denervation)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content